Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$26.0 million.

  • Lineage Cell Therapeutics' Non Operating Income fell 319487.49% to -$26.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.3 million, marking a year-over-year decrease of 176381.88%. This contributed to the annual value of $2.9 million for FY2024, which is 9958.65% up from last year.
  • Lineage Cell Therapeutics' Non Operating Income amounted to -$26.0 million in Q3 2025, which was down 319487.49% from -$10.6 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Non Operating Income registered a high of $5.6 million during Q1 2021, and its lowest value of -$26.0 million during Q3 2025.
  • In the last 5 years, Lineage Cell Therapeutics' Non Operating Income had a median value of $103000.0 in 2024 and averaged -$1.5 million.
  • Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Non Operating Income was 219320.39% (2025), while the steepest drop was 1135957.45% (2025).
  • Lineage Cell Therapeutics' Non Operating Income (Quarter) stood at $229000.0 in 2021, then rose by 20.96% to $277000.0 in 2022, then surged by 227.44% to $907000.0 in 2023, then soared by 105.07% to $1.9 million in 2024, then plummeted by 1496.02% to -$26.0 million in 2025.
  • Its Non Operating Income stands at -$26.0 million for Q3 2025, versus -$10.6 million for Q2 2025 and $2.4 million for Q1 2025.